Erasca, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ERAS research report →
Companywww.erasca.com
Erasca, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors.
- CEO
- Jonathan E. Lim
- IPO
- 2021
- Employees
- 103
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $3.46B
- P/E
- -12.22
- P/S
- 0.00
- P/B
- 8.60
- EV/EBITDA
- -26.85
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -77.01%
- ROIC
- -32.56%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-124,546,000 · 22.95%
- EPS
- $-0.44 · 36.23%
- Op Income
- $-131,405,000
- FCF YoY
- 27.58%
Performance & Tape
- 52W High
- $24.28
- 52W Low
- $1.06
- 50D MA
- $14.76
- 200D MA
- $7.35
- Beta
- 0.68
- Avg Volume
- 6.73M
Get TickerSpark's AI analysis on ERAS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 1, 26 | Garner Ebun | other | 80,000 |
| Apr 1, 26 | Garner Ebun | other | 80,000 |
| Apr 1, 26 | Garner Ebun | sell | 80,000 |
| Mar 4, 25 | Morris Shannon | other | 20,000 |
| Mar 4, 26 | Morris Shannon | other | 20,000 |
| Mar 4, 26 | Morris Shannon | sell | 20,000 |
| Jan 29, 26 | Lim Jonathan E | other | 2,000,000 |
| Jan 29, 26 | Chacko David M. | other | 640,000 |
| Dec 15, 25 | Chacko David M. | other | 17,793 |
| Jan 29, 26 | Morris Shannon | other | 625,000 |
Our ERAS Coverage
We haven't published any research on ERAS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ERAS Report →